Detailed instructions for usage and dosage of cimepilimab

Cemiplimab (Cemiplimab) is a humanized IgG4-type PD-1 monoclonal antibody that blocks the binding of programmed death receptor 1 (PD-1) and its ligand PD-L1/PD-L2, thereby restoring the immune attack function of T cells against tumors. It has shown significant efficacy in a variety of solid tumors and has been approved by the FDA for multiple indications. According to its official instructions, the recommended usage and dosage of cimepilimab will vary slightly depending on the type of cancer being treated, but the common dosage is 350 mg intravenously every 3 weeks and continued until the disease progresses or intolerable toxicity occurs.

Cimepilimab is widely recommended as a first-line or alternative treatment option for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and locally advanced or metastatic basal cell carcinoma (BCC) who are inoperable with surgery or radiotherapy. During treatment, an intravenous infusion of 350 mg is usually given every three weeks, with each infusion lasting no less than 30 minutes, and the maximum duration of treatment is no more than 24 months. This treatment course setting not only takes into account the characteristics of immunotherapy to produce sustained anti-tumor effects, but also helps reduce immune-related adverse events (irAEs) caused by long-term use.

In the field of non-small cell lung cancer (NSCLC), cimepilimab is mainly suitable for patients with locally advanced or metastatic NSCLC with high PD-L1 expression levels (TPS ≥ 50%) and no driver gene mutations such as EGFR and ALK. Its usage is also 350 mg intravenously every three weeks until disease progression or intolerable toxicity. In this indication, cimepilimab has shown good survival benefits as a single-agent immunotherapy or in combination with chemotherapy, and is particularly suitable for immune-sensitive patient groups.

Immune-related toxicity needs to be closely monitored during the administration of cimepilimab. In addition, the drug does not require specific prodrug treatment before use and is suitable for outpatient infusion management, which greatly improves patient convenience and compliance.

Reference materials:https://www.libtayohcp.com/